Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study

Ibuki Tsuru(University of Tokyo Hospital), Haruki Kume(The University of Tokyo), Taketo Kawai(National Center for Global Health and Medicine), Yukari Uemura(University of Tokyo Hospital), Jun Kamei(The University of Tokyo), Tappei Takada(University of Tokyo Hospital), Michio Noda(Teikyo University), Yusuke Sato(Tokyo Metropolitan Tama Medical Center), Hiroaki Nishimatsu(Memorial Hospital of South Bend), Masato Kano(Maizuru Municipal Hospital), Ryo Tanaka(Kawasaki Medical School), Takashi Murata(Kyoto Medical Center), Satoru Taguchi(Iwate Medical University), Masashi Shiozaki(Shinshu University), Tomoyuki Kaneko(Teikyo University), Jimpei Miyakawa(Kyorin University), Daisuke Obinata(Nihon University), Takehiro Tanaka(Okayama University), Hiroshi Fukuhara(Kyorin University), Yuta Yamada(Yamagata University), Yukio Yamada(Musashino Red Cross Hospital), Masashi Koshiba(Shinshu University), Tetsuya Fujimura(Jichi Medical University), Jun Takahashi(Tokyo Medical University), Yu Nakamura(Kyorin University), Sayuri Takahashi(Tokyo Medical University), Akihiro Naito(Tokyo Metropolitan Bokutoh Hospital), Yoshiyuki Akiyama(Shinshu University), Tohru Nakagawa(Teikyo University), Satoru Takahashi(Nihon University), Hayato Hoshina(Jichi Medical University), Shohei Suda(Memorial Hospital of South Bend), Aya Niimi(University of Tokyo Hospital), Yoshifumi Miyauchi(Jichi Medical University), Nozomi Sugiyama(Musashino Red Cross Hospital), Shigenori Kakutani(The University of Tokyo)
Japanese Journal of Clinical Oncology
July 9, 2026
Cited by 0


Related Papers